Menu
ncarol.com
  • Home
  • Business
  • Books
  • Real Estate
  • Marketing
  • Arts
  • Property
  • Entertainment
  • New Release
ncarol.com

Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
ncarol.com/10212254

Trending...
  • ReadyCommunities Partnership of CCROA Announces National Service Awardees Who Helped Save Passengers from the Derailed Train Near Rural Mendon
  • How Do You Build Generational Wealth?
  • NEMTAC® Brings Innovation to Accreditation Industry with the Launch of Collaborative Network Built on Distributed Ledger Technology
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.

Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET

The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.

More on ncarol.com
  • INshed Now Offers Nationwide Shipping of Fully-Assembled, Eco-Friendly Backyard Offices
  • Entrinsik Appoints Madhavi W. Chandra as Chief Product Officer
  • Award-winning singer-songwriter Ronnie Call and The Waterz Edge Band has a new tune
  • Golden Ticket Productions Launches New Website
  • Granite Ridge Townhomes Now Available in Rolesville

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Contacts

Investor Contact:

Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com

Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Ohio County Commission President & Founder of the Cincinnati Black Music Walk of Fame, Alicia Reece, Announces Grand Opening of New Tourism Attraction
  • New York Komedians Presents an Evening of Laughs at Broadway
  • Redefining Professional Spaces: The Rise of Dual-Purpose Backyard Office Sheds in America
  • How Do You Build Generational Wealth?
  • Registration is Now Open for the 2023 CGI Integrated Care Conference
  • Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
  • Studeo dévoile StudAI : l'Intelligence Artificielle au service de l'éducation
  • EMH Productions Announce 'Live for Liberty' Charity Concert in Los Angeles Supporting "Woman, Life, Freedom" Movement in Iran
  • NEMTAC® Brings Innovation to Accreditation Industry with the Launch of Collaborative Network Built on Distributed Ledger Technology
  • Latino Leaders Network to Honor Mayor Kate Gallego of Phoenix with the Antonio Villaraigosa Leadership Award at the 38th Tribute to Mayors
  • New for spring and summer at Lakeview at Fontana resort spa in North Carolina
  • Century Fasteners Corp. – Robert D. Botticelli, Hired
  • Duke Energy urges customers to plan for 2023 hurricane season
  • Levinger-Regens Analytics Reveals New Energy Outlook
  • UVify Unveils the Groundbreaking SLAMDAQ
  • Dancing Numbers Unveils Google Sheets QuickBooks Integration, Streamlining Data Import, Export, and Deletion
  • ReadyCommunities Partnership of CCROA Announces National Service Awardees Who Helped Save Passengers from the Derailed Train Near Rural Mendon
  • LOWE'S COMPANIES, INC. ANNOUNCES 5% INCREASE TO QUARTERLY CASH DIVIDEND
  • Bitcoin Mining Capacity Reaches 350 Exahashes/second
  • Up To 70% Off! Alibonnie Graduation Season Wig Surprise Discount
_catLbl0 _catLbl1

Popular on ncarol.com

  • SEE Upcoming Event with the Financial Community
  • Josh Greenwald Recruited to Lead Sunset Properties Group into the Commercial Landscape
  • South Asian Streaming Service 'Cpics' Announces Platform is Live
  • Catapult Lakeland to host the VC Fast Pitch on June 8th
  • Esteem Dental Now Has A New Pediatric Brand To Serve The Greater Orlando, FL Area
  • EclecticIQ launches version 3.0 of its flagship threat intelligence platform, Intelligence Center
  • Dr. Sean Freeman Receives Awards for Excellence, Innovation, and Lifetime Achievements
  • The World's No.1 Superstar is back with a new single and an epic alien-themed music video for "Frustrated."
  • Michigan Moves Month: Move More in May
  • What Donald Trump Doesn't Seem To Know About Women

Similar on ncarol.com

  • Calvetta Phair, CEO of America's Workforce Solution, LLC, accepted into the Nasdaq Entrepreneurial Center, 'Milestone Circles' Program
  • Australian Battery Recycling Technology Startup Advances Its Innovative Battery Metals Recovery Process
  • Trump Bus Tour sponsored by Legacy PAC will roll into the Georgia GOP State convention June 9th and 10th Columbus Georgia
  • Pettit Kohn Welcomes Esteemed Attorney John E. Drazkowski to the Arizona Team
  • Fuse Oncology Closes Funding Round with Support from Leading Health Systems in the Southern U.S.
  • Golden Ticket Productions Launches New Website
  • RXO Expands Carrier Rewards Program to Include Services from Simplex Group
  • Orbex Launches New ZERO Spread Trading Account with $1 Commission per Side
  • Registration is Now Open for the 2023 CGI Integrated Care Conference
  • Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
Copyright © 2023 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute